about akston
process
pipeline
news
careers
contact
NEWS
29 September 2021
The Next COVID Challenge: Building an Arsenal of Vaccines
The Next COVID Challenge: Building an Arsenal of Vaccines
7 September 2021
Second-generation vaccines offer a chance to correct flaws in early vaccination campaigns
Second-generation vaccines offer a chance to correct flaws in early vaccination campaigns
31 August 2021
More accessible Covid-19 vaccines and community engagement key for rural areas
More accessible Covid-19 vaccines and community engagement key for rural areas
30 August 2021
In the pipeline: What the next wave of COVID-19 vaccines could look like
In the pipeline: What the next wave of COVID-19 vaccines could look like
20 August 2021
Second Wave of COVID-19 Vaccines Could Resolve Vaccine Inequity
Second Wave of COVID-19 Vaccines Could Resolve Vaccine Inequity
5 August 2021
Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine
Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine
2 August 2021
mRNA deals will not solve Africa’s vaccine shortfall, but the second generation of vaccines may
mRNA deals will not solve Africa’s vaccine shortfall, but the second generation of vaccines may
21 July 2021
Could second-generation vaccines accelerate Africa’s slow immunisation drive?
Could second-generation vaccines accelerate Africa’s slow immunisation drive?
21 July 2021
Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale
Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale
15 July 2021
Todd Zion, PhD, CEO and Repeat Founder, “Magical Proteins”
Todd Zion, PhD, CEO and Repeat Founder, “Magical Proteins”
1
6
7
8
11
